Drugs / RRG001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06412224 | Dec 2023 → Dec 2024 overdue | proliferative diabetic retinopathy | Li Xiaorong | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06141460 | Dec 2023 → Apr 2026 overdue | wet macular degeneration | Shanghai Refreshgene Technology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RRG001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06141460 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “RRG001 Gene Therapy” NCT06141460 ↗ |
| Route | Other | “Administered by subretinal injection.” NCT06412224 ↗ |